TITLE

Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?

AUTHOR(S)
Bernstein, Charles N.; Blanchard, James F.; Metge, Colleen; Yogendran, Marina
PUB. DATE
December 2003
SOURCE
American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2784
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: There is increased interest in determining whether 5-aminosalicylate (5-ASA) use can prevent the development of colorectal cancer (CRC) among patients with inflammatory bowel disease (IBD). The aim of this study was to determine whether use of 5-ASA was associated with a reduced risk of CRC in these patients. METHODS: We extracted from our population-based University of Manitoba Inflammatory Bowel Disease Epidemiology Database the number of patients with a new diagnosis of CRC between the years 1997 and 2000. From within our Inflammatory Bowel Disease Epidemiology Database we extracted a control group of IBD patients who did not develop CRC matched to the case group who did develop CRC by age, sex, diagnosis, year of diagnosis, and geographic area of residence. We linked cases and controls with Manitoba Health's Drug Program Information Network to study 5-ASA use within 2 yr before CRC diagnosis. The Drug Program Information Network database is a population-based database that was established in 1995 and that records all prescription drugs. RESULTS: There were 25 cases of IBD identified as having CRC. These were matched with 348 cases of IBD who did not develop CRC. CRC cases were more likely to be exposed to 5-ASA (odds ratio = 1.46; 95% CI = 0.58-3.73) but this result was not statistically significant. The mean total days of use was 400.9 days ± 185.9 among CRC cases versus 420.2 days ± 241.7 among non-CRC cases (p = 0.92). The prescribed daily dose was 2295 mg/day ± 1041 mg among CRC cases and 1811 mg ± 520 mg among controls (p = 0.21). CONCLUSION: These data do not support 5-ASA as protective in preventing CRC.
ACCESSION #
15182476

 

Related Articles

  • Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis. Singh, Siddharth; Loftus, Edward V; Talwalkar, Jayant A // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1417 

    The course of inflammatory bowel disease (IBD) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complex, with several IBD-, PSC-, and transplant-related factors interplaying with each other. Approximately one-third of patients with known IBD improve, and one-third...

  • Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy. von Roon, Alexander C.; Karamountzos, Leonidas; Purkayastha, Sanjay; Reese, George E.; Darzi, Ara W.; Teare, Julian P.; Paraskeva, Paraskevas; Tekkis, Paris P. // American Journal of Gastroenterology;Apr2007, Vol. 102 Issue 4, p803 

    OBJECTIVES: Fecal calprotectin (FC) is a relatively new marker of intraluminal intestinal inflammation. Using meta-analytical techniques, the study aimed to evaluate the diagnostic precision of FC for inflammatory bowel disease (IBD) and colorectal cancer (CRC) in adults and children. METHODS:...

  • Sulfasalazine Desensitization in Children and Adolescents with Chronic Inflammatory Bowel Disease. Tolia, Vasundhara // American Journal of Gastroenterology;Aug1992, Vol. 87 Issue 8, p1029 

    Sulfasalazine is an important therapeutic agent in the management of chronic inflammatory bowel disease (CIBD). Unfortunately, adverse reactions to this drug have been reported in 5-55% of treated patients. These include dose-related side effects like nausea, malaise, and headache or...

  • Probiotic therapy in gut.  // GP: General Practitioner;10/1/2004, p19 

    This article reports the results of a study, conducted by researchers at Dundee University, which states that a pro-biotic therapy, which raises levels of "good bacteria" in the gut, may help reduce symptoms of inflammatory bowel disease. Researchers analyzed the populations of micro flora in...

  • The impact of intestinal failure on oral drug absorption: a review. Ward, Nicola // Journal of Gastrointestinal Surgery;Jun2010, Vol. 14 Issue 6, p1045 

    Introduction: Intestinal failure is a complex gastroenterological condition that occurs as a result of reduced intestinal absorption of nutrients and/or water and electrolytes. Without treatment, nutritional depletion and/or dehydration will result. It can be acute or chronic and...

  • Use of Pharmaceuticals by Inflammatory Bowel Disease Patients: A Population-Based Study. Metge, Colleen J.; Blanchard, James F.; Peterson, Sandra; Bernstein, Charles N. // American Journal of Gastroenterology;Dec2001, Vol. 96 Issue 12, p3348 

    OBJECTIVES: In 1996 we created the population-based University of Manitoba Inflammatory Bowel Disease {IBD) Database. In 1994, Manitoba Health established the Drug Program Information Network (DPIN). which identified all ambulatory prescription drugs dispensed to each individual resident of the...

  • Inflammatory bowel disease—be aware of the mimics. Ravens, A.-F. // Gut;Mar2006, Vol. 55 Issue 3, p333 

    The article illustrates the result of the clinical tests of a 43-year old male nurse practitioner with inflammatory bowel disease. In colonoscopy, the rectum showed swollen and aphthous ulcers with pus on them. The patient has a strong history of colon cancer presented with bloody diarrhea....

  • The rise and rise of probiotics. Gibson, Glenn // Biologist;May2005, Vol. 52 Issue 2, p95 

    The article presents information about probiotics. The approach of using diet to prophylactically manage disorder is both user-friendly and attractive to the consumer. Current marketing strategies target improved resistance to infections, irritable bowel syndrome, chronic gut disorder, lactose...

  • Risk Factors of Colorectal Cancer in Inflammatory Bowel Disease. Bansal, Pradeep; Sonnenberg, Amnon // American Journal of Gastroenterology;Jan1996, Vol. 91 Issue 1, p44 

    Background: It is unknown whether colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) behaves differently from regular CRC in patients without IBD. A case-control study was conducted to compare CRC in patients with and without underlying IBD. Methods: The Department of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics